This is the first pathway out of two pathways which deals with DNA damage response. It has two central gene products (ATM and ATR) which are connected to the sources of DNA damage (in blue). The two central genes can be divides furthermore into their most important genes. In the ATM pathway are the most important genes TP53 and CHEK2 and on the other hand in the ATR pathway is this CHEK1. If it is not mentioned different, the processes take place in the cell cytoplasm. The goal of this first pathway is to give an overview of the most important gene products, processes and changes in the cell condition through the DNA damage response pathway and at the same time to keep it clearly arranged. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP707 CPTAC Assay Portal]

Authors

Jonas Hummel , Alex Pico , Stan Gaj , Martina Summer-Kutmon , Martijn Van Iersel , Christine Chichester , Daniela Digles , Kristina Hanspers , Zahra Roudbari , Egon Willighagen , Ryan Miller , Finterly Hu , Eric Weitz , and Vanessa Sousa

Cited In

• 
• 
• 
• 
• 
• 
• 

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organism

Homo sapiens

Communities

CPTAC PancCanNet

Annotations

Pathway Ontology: stress response pathway DNA damage response pathway p53 signaling pathway

Participants

References

1. Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003 Nov 24;22(53):8590–607. PubMed Europe PMC Scholia
2. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet. 2004 Feb;36(2):147–50. PubMed Europe PMC Scholia
3. Zhou B-BS, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer. 2004 Mar;4(3):216–25. PubMed Europe PMC Scholia
4. Pagano M, Jackson PK. Wagging the dogma; tissue-specific cell cycle control in the mouse embryo. Cell. 2004 Sep 3;118(5):535–8. PubMed Europe PMC Scholia
5. Ljungman M, Lane DP. Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer. 2004 Sep;4(9):727–37. PubMed Europe PMC Scholia
6. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004 Nov 15;18(22):2699–711. PubMed Europe PMC Scholia
7. Reshmi SC, Gollin SM. Chromosomal instability in oral cancer cells. J Dent Res. 2005 Feb;84(2):107–17. PubMed Europe PMC Scholia
8. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol. 2005 Jan;6(1):44–55. PubMed Europe PMC Scholia
9. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005 Mar;5(3):189–200. PubMed Europe PMC Scholia
10. Harrison JC, Haber JE. Surviving the breakup: the DNA damage checkpoint. Annu Rev Genet. 2006;40:209–35. PubMed Europe PMC Scholia
11. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 2006 Sep;7(9):667–77. PubMed Europe PMC Scholia
12. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006 Nov;6(11):846–56. PubMed Europe PMC Scholia
13. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006 Dec;6(12):909–23. PubMed Europe PMC Scholia
14. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007 Apr;8(4):275–83. PubMed Europe PMC Scholia
15. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007 Jul;7(7):495–507. PubMed Europe PMC Scholia
16. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007 Oct;8(10):735–48. PubMed Europe PMC Scholia
17. Löbrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 2007 Nov;7(11):861–9. PubMed Europe PMC Scholia
18. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer. 2007 Dec;7(12):925–36. PubMed Europe PMC Scholia
19. Chargari C, Toillon RA, Macdermed D, Castadot P, Magné N. Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Lancet Oncol. 2009 Jan;10(1):53–60. PubMed Europe PMC Scholia
20. Gong H, Cao Y, Han G, Zhang Y, You Q, Wang Y, et al. p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage. Int J Oncol. 2017 May;50(5):1785–91. PubMed Europe PMC Scholia